机译:第二次尝试与达沙替尼停止的TKI停止,在未经伊马替尼尝试后无菌缓解治疗:Dasatinib(TROD)试验完成的免费缓解
Univ Hlth Network Dept Med Oncol &
Hematol Princess Margaret Canc Ctr Toronto ON Canada;
Univ Montreal Dept Lab Hematol Hop Maisonneuve Rosemont Montreal PQ Canada;
BC Canc Leukemia BMT Program BC Vancouver BC Canada;
Univ Calgary Calgary AB Canada;
Ottawa Hosp Res Inst Ottawa ON Canada;
Queen Elizabeth 2 Hlth Sci Ctr Halifax NS Canada;
Univ Laval CHU Quebec Hop Enfants Jesus Div Hematol &
Med Oncol Quebec City PQ Canada;
London Hlth Sci Ctr Div Hematol Dept Med London ON Canada;
Univ Alberta Hosp Edmonton AB Canada;
McGill Univ Hlth Ctr Montreal PQ Canada;
Cancercare Manitoba Winnipeg MB Canada;
Univ Hlth Network Princess Margaret Canc Ctr Blood &
Marrow Transplant Program Dept Med Oncol &
Princess Margaret Canc Ctr Adv Mol Diagnost Lab Toronto ON Canada;
Juravinski Canc Ctr Hamilton Hlth Sci Ctr Hamilton ON Canada;
机译:第二次尝试与达沙替尼停止的TKI停止,在未经伊马替尼尝试后无菌缓解治疗:Dasatinib(TROD)试验完成的免费缓解
机译:另一种方法 - 酪氨酸激酶抑制剂(TKI)脱升升级 - 停止TKIS以实现无需缓解
机译:TKI停止时的数字液滴PCR在慢性相慢性骨髓白血病患者的预测性免除抗缓解结果
机译:伊马替尼停药后FIP1L1-PDGFRA阳性的嗜酸性粒细胞/淋巴瘤无治疗缓解
机译:在CML中发展的治疗策略 - 从早期和深度分子反应转移到TKI停药和无期治疗中:是否需要长期试验结果?